EA202091684A1 - Новый галактозидный ингибитор галектинов - Google Patents

Новый галактозидный ингибитор галектинов

Info

Publication number
EA202091684A1
EA202091684A1 EA202091684A EA202091684A EA202091684A1 EA 202091684 A1 EA202091684 A1 EA 202091684A1 EA 202091684 A EA202091684 A EA 202091684A EA 202091684 A EA202091684 A EA 202091684A EA 202091684 A1 EA202091684 A1 EA 202091684A1
Authority
EA
Eurasian Patent Office
Prior art keywords
galactoside
new
formula
galectin
galectin inhibitor
Prior art date
Application number
EA202091684A
Other languages
English (en)
Inventor
Фредрик Зеттерберг
Original Assignee
Галекто Биотек Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галекто Биотек Аб filed Critical Галекто Биотек Аб
Publication of EA202091684A1 publication Critical patent/EA202091684A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению общей формулы (I), где пиранозное кольцо представляет собой a-D-галактопиранозу, R1 выбран из группы, состоящей из формулы (II), где звездочка * означает атом углерода гетероароматического кольца, который ковалентно присоединен к триазольной группе формулы (I). Соединение формулы (I) подходит для применения в способе лечения расстройства, касающегося связывания галектина, такого как галектин-1, с лигандом, у млекопитающего, такого как человек.
EA202091684A 2018-01-10 2019-01-09 Новый галактозидный ингибитор галектинов EA202091684A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18150959 2018-01-10
PCT/EP2019/050467 WO2019137971A1 (en) 2018-01-10 2019-01-09 Novel galactoside inhibitor of galectins

Publications (1)

Publication Number Publication Date
EA202091684A1 true EA202091684A1 (ru) 2020-12-04

Family

ID=60953765

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091684A EA202091684A1 (ru) 2018-01-10 2019-01-09 Новый галактозидный ингибитор галектинов

Country Status (10)

Country Link
US (2) US11046725B2 (ru)
EP (1) EP3737686A1 (ru)
JP (1) JP2021510692A (ru)
KR (1) KR20200108303A (ru)
CN (1) CN111699193A (ru)
BR (1) BR112020013647A2 (ru)
CA (1) CA3086092A1 (ru)
EA (1) EA202091684A1 (ru)
MX (1) MX2020007391A (ru)
WO (1) WO2019137971A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
EA202091684A1 (ru) * 2018-01-10 2020-12-04 Галекто Биотек Аб Новый галактозидный ингибитор галектинов
EP3867260A1 (en) * 2018-10-15 2021-08-25 Galecto Biotech AB Galactoside inhibitor of galectins
US20230014870A1 (en) * 2019-07-03 2023-01-19 Galecto Biotech Ab Novel galactoside inhibitor of galectins
TW202134214A (zh) * 2020-03-04 2021-09-16 瑞士商先正達農作物保護公司 用於製備具有3-含硫取代基的5-氯-吡啶-2-甲酸醯胺以及甲酸鹽之方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849607B2 (en) 2001-05-09 2005-02-01 Health Research, Inc. Galectin recognized photosensitizers for photodynamic therapy
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
CN102439021B (zh) 2009-04-28 2015-09-02 格莱克特生物技术公司 半乳凝素的新型半乳糖苷抑制剂
CN104822382B9 (zh) 2012-10-10 2019-01-18 卡莱克汀医疗有限公司 用于治疗糖尿病性肾病和相关疾病的半乳糖分支的糖类化合物
CN104755088A (zh) 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
WO2016113335A1 (en) * 2015-01-16 2016-07-21 Galecto Biotech Ab Novel galactoside inhibitor of galectins
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
EP3484904A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
CN109563120B (zh) * 2016-07-12 2022-12-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
EA202091684A1 (ru) * 2018-01-10 2020-12-04 Галекто Биотек Аб Новый галактозидный ингибитор галектинов

Also Published As

Publication number Publication date
US11046725B2 (en) 2021-06-29
KR20200108303A (ko) 2020-09-17
BR112020013647A2 (pt) 2020-12-01
MX2020007391A (es) 2020-09-03
CA3086092A1 (en) 2019-07-18
EP3737686A1 (en) 2020-11-18
US20200347089A1 (en) 2020-11-05
US20210284678A1 (en) 2021-09-16
CN111699193A (zh) 2020-09-22
US11827666B2 (en) 2023-11-28
JP2021510692A (ja) 2021-04-30
WO2019137971A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
EA202091684A1 (ru) Новый галактозидный ингибитор галектинов
EP3828191A3 (en) Novel galactoside inhibitor of galectins
MX2023011282A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2020011564A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
CR20200518A (es) Piridozinonas como inhibidores de parp7
SA522433087B1 (ar) Sos1 مثبطات
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
TR201909093T4 (tr) Hidroksi içeren FXR (NR1H4) modüle edici bileşikleri.
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
NZ728120A (en) Histone demethylase inhibitors
EA201201648A1 (ru) Стимуляторы sgc
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
MX2012002641A (es) Inhibidores de cinasa janus (jak).
EA200970512A1 (ru) Лечение по поводу множественной миеломы
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
SA516371323B1 (ar) مركبات بيرازول فلورو فينيل
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
MX2022001167A (es) Metodo para el tratamiento de una composicion que comprende vainillina natural.
PH12018501873A1 (en) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative